The initial project, bio-simulation of BioLineRx’s patented BL-1020 for the treatment of schizophrenia, will serve as a proof of concept using Optimata’s technology and provide a basis for future collaborations.
The collaboration will draw upon Optimata’s biomathematical and disease modeling expertise which enables an accurate portrayal of the dynamics of disease processes and detailed predictions of drug effects. The collaboration will demonstrate how using Optimata’s Virtual Patient technology can aid in shortening preclinical development time and provide guidance for focused clinical trials.
BioLineRx’s patented BL-1020, in multiple animal models of schizophrenia, has shown safety and efficacy matching that of both typical and atypical antipsychotics, without the metabolic or extrapyramidal side effects associated with each. BioLineRx recently completed a Pre-Investigational New Drug meeting with the FDA and anticipates initiation of clinical testing in early 2006.
“We believe that Optimata’s ability to provide computer simulation of the complete and detailed drug-patient interaction can play an important role in the development of new molecules for the treatment of a wide array of indications,” said Dr Morris Laster, CEO of BioLineRx.